VEGFA and wet macular degeneration: The anti-vascular endothelial growth factor (anti-VEGF) medications, ranibizumab (Lucentis®) and aflibercept (Eylea®), were licensed during the evaluation period to treat wet age-related macular degeneration (AMD), and retinal vein occlusion (only central vein occlusions (CVO) for aflibercept), and ranibizumab was also licensed for the treatment of diabetic macular edema (DME) [1, 2].